2. Search Result
Search Result
Results for "

Growth hormone secretagogue receptor

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

5

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50844
    Ibutamoren Mesylate
    5 Publications Verification

    MK-677; MK-0677

    		 GHSR Endocrinology
    Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.
    Ibutamoren Mesylate
  • HY-19884B
    Relamorelin TFA
    1 Publications Verification

    RM-131 TFA; BIM-28131 TFA

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-10199A
    Ibutamoren
    5 Publications Verification

    MK-677 free base; MK-0677 free base

    		 GHSR Insulin Receptor Neurological Disease Metabolic Disease
    Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
    Ibutamoren
  • HY-15243
    Capromorelin Tartrate

    CP 424391-18

    		 GHSR Neurological Disease Endocrinology
    Capromorelin Tartrate is an orally active, potent growth hormone secretagogue receptor (GHSR) agonist, with Ki of 7 nM for hGHS-R1a.
    Capromorelin Tartrate
  • HY-U00433
    JMV 2959
    3 Publications Verification

    		 GHSR Neurological Disease Endocrinology
    JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM.
    JMV 2959
  • HY-113906A
    (αR,8aS)-GSK1614343

    		GHSR Metabolic Disease
    (αR,8aS)-GSK1614343 is the isomer of GSK1614343 (HY-113906). GSK1614343 is the potent antagonist of growth hormone secretagogues type 1a (GHS1a) receptors .
    (αR,8aS)-GSK1614343
  • HY-P1366
    des-​Gln14-​Ghrelin
    1 Publications Verification

    		 GHSR Metabolic Disease
    des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
    des-​Gln14-​Ghrelin
  • HY-U00433A
    JMV 2959 hydrochloride
    3 Publications Verification

    		 GHSR Neurological Disease Endocrinology
    JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells.
    JMV 2959 hydrochloride
  • HY-50760
    L-692585

    		GHSR Endocrinology
    L-692585 is a potent and nonpeptidyl growth hormone secretagogue receptor (GHS-R1a) agonist, with a Ki of 0.8 nM. L-692585 acts directly on somatotropes causing GH release .
    L-692585
  • HY-19884
    Relamorelin

    RM-131; BIM-28131

    		 GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-10957
    L-692429

    MK-0751

    		 GHSR Metabolic Disease
    L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 binds to G protein-coupled receptor with a Ki of 63 nM .
    L-692429
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-119125
    BMS-317180

    		GHSR Cancer
    BMS-317180 is an orally active and potent growth hormone secretagogue receptor (GHS-R) agonist (EC50=7.9 nM). BMS-317180 stimulates endogenous growth hormone (GH) release. BMS-317180 is promising for research of age-related frailty, osteoporosis, and cancer cachexia .
    BMS-317180
  • HY-129207
    JMV 3002

    		GHSR Endocrinology
    Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor that stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. JMV3002 is a potent ghrelin receptor antagonist with an IC50 value of 1.1 nM in vitro. 80 μg/kg, JMV3002 inhibits hexarelin-stimulated food intake by as much as 98% in rats. JMV3002 alone does not elicit growth hormone release nor does it inhibit hexarelin-stimulated growth hormone secretion when tested in infant rats at a dose of 160 μg/kg.
    JMV 3002
  • HY-113906
    GSK1614343

    		GHSR Metabolic Disease
    GSK1614343 is the potent antagonist of growth hormone secretagogues type 1a (GHS1a) receptors. GSK1614343 inhibits the calcium response induced by ghrelin with a pIC50 value of 7.90. GSK1614343 represents a useful tool to investigate the physiological relevance of the ghrelin system in rat models .
    GSK1614343
  • HY-14495
    BMS-604992

    EX-1314

    		 GHSR Metabolic Disease
    BMS-604992 (EX-1314) is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (Ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 can stimulate food intake in rodents .
    BMS-604992
  • HY-10957A
    L-692429 hydrochloride

    MK-0751 hydrochloride

    		 GHSR Metabolic Disease
    L-692429 (MK-0751) hydrochloride is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 hydrochloride binds to G protein-coupled receptor with a Ki of 63 nM .
    L-692429 hydrochloride
  • HY-P1366A
    des-​Gln14-​Ghrelin TFA

    		GHSR Metabolic Disease
    des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
    des-​Gln14-​Ghrelin TFA
  • HY-176995
    AZ-GHS-38

    		GHSR Metabolic Disease
    AZ-GHS-38 (compound 38) is an orally active CNS-penetrant inverse agonist of growth hormone secretagogue receptor (GHS-R1a) with an IC50 of 6.7 nM. AZ-GHS-38 results in acute reduction of food intake in wild-type mice. AZ-GHS-38 can be used for anti-obesity research .
    AZ-GHS-38
  • HY-14495B
    BMS-604992 dihydrochloride

    EX-1314 dihydrochloride

    		 GHSR Metabolic Disease
    BMS-604992 (EX-1314) dihydrochloride is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 dihydrochloride demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 dihydrochloride can stimulate food intake in rodents .
    BMS-604992 dihydrochloride
  • HY-14495A
    BMS-604992 free base

    EX-1314 free base

    		 GHSR Metabolic Disease
    BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 free base can stimulate food intake in rodents .
    BMS-604992 free base
  • HY-173271
    GHSR-1a agonist-1

    		GHSR Endocrinology
    GHSR-1a agonist-1 (Compound 4b) is an orally active agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a), with an EC50 of 0.49 nM. GHSR-1a agonist-1 can effectively stimulate the release of endogenous growth hormone by activating GHSR-1a. GHSR-1a agonist-1 administered orally at a dose as low as 0.1 mg/kg can increase the body weight and body length of 4-week-old rats. GHSR-1a agonist-1 can be used in the research field of growth and development retardation in children .
    GHSR-1a agonist-1
  • HY-186165
    KARI 101

    		Phosphatase AMPK Calcium Channel GHSR Neurological Disease
    KARI 101 is a blood-brain barrier permeable acid sphingomyelinase (ASM) inhibitor. KARI 101 directly inhibits ASM activity and reduces ceramide production. KARI 101 induces Ca 2+ mobilization, activates AMPK and triggers GHSR1α internalization. KARI 101 can be used for the research of Alzheimer's disease .
    KARI 101

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: